Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Comment by RevJameson Jul 06, 2020 8:36pm
167 Views
Post# 31231619

RE:RE:RE:RE:Fair Share Value for PMX from Prospectus

RE:RE:RE:RE:Fair Share Value for PMX from Prospectus
mercedesman wrote: It would be a off the top guess, but I'd be inclined to take 80% of your profit figure to arrive at EBITDA, to allow for G&A & other ongoing expenses.

This depends on what they do as far as executive compensation (e.g option grants are expensed), how well they manage things (e.g why the $ 1.7M cost to do a DA?), and do they stick to the program of doing little to no marketing/PR/selling/etc/ presumably all the responsibility of Baxter going forward (as Spectral stated in their prospectus)


Great! So if I'm understanding MM right, multiplying profit by 80% EBITDA, gives us:

165,000 target population * 40% market penetration * 2 columns * $7500US * 60% revenue share * 70% profit * 80% EBITDA * 10 multiplier = $3,326,400,000 US / 262,586,865 shares = $12.67 US/share = $17.10 CAD/share

(I also heard that a 10 multiplier is fitting for a CAD company, but 15-20 might be bettter for a US-listed company.)

This is just for the pump portion of the company. Open to correction.  Do your own due diligence!


Bullboard Posts